



FACSIMILE

STATE PHARMACEUTICALS CORPORATION

16th Floor, "Mehewara Piyasa" 41, Kirula Road, Colombo 05, Sri Lanka.

Telephone : (00) 94- 11 - 2582509

Fax : (00) 94 - 11 - 2582496

E-Mail: pharma.manager@spc.lk

NO. OF PAGES

TRANSMITTED :
IF ALL PAGES
NOT RECEIVED
PLEASE TELEPHONE:



FAX TO : M/s.

FAX NO :

DATE :

BIDDING DOCUMENT FOR INVITATION OF RESTRICTED BIDS (DPC)
FOR THE SUPPLY OF DRUGS FOR EMERGENCY PURCHES FROM INDIA WITH
FACILITY OF INDIAN CREDIT LINE

BID NO. : DHS/ICL/X/008/2022

CLOSING AT 9.00 A.M. SRI LANKA TIME ON : 31.03.2022

State Pharmaceuticals Corporation hereby invite your lowest prices for the supply of the item/s listed in the Annex 1 , which is for use in Government Medical Institutions.

Yours faithfully

STATE PHARMACEUTICALS CORPORATION OF SRI LANKA

PROCUREMENT OFFICER
DHS - [PHARMACEUTICALS]



STATE PHARMACEUTICALS CORPORATION OF SRI LANKA

(ESTABLISHED UNDER THE STATE INDUSTRIAL CORPORATIONS ACT, NO. 49 OF 1957)

16th Floor, "Mehewara Piyasa" 41, Kirula Road, Colombo 05 Sri Lanka

Telephone : (00) 94- 11 - 2582509

Fax : (00) 94 - 11 - 2582496

E-Mail: pharma.manager@spc.lk

Dear Sirs,

BIDDING DOCUMENT FOR INVITATION OF RESTRICTED BIDS (DPC)
FOR THE SUPPLY OF DRUGS FOR EMERGENCY PROCUREMENT FROM
INDIA WITH FACILITY OF INDIAN CREDIT LINE

BID NO. /BID REFERENCE : DHS/ICL/X/008/2022
CLOSING AT 9.00 am SRI LANKA TIME ON : 31.03.2022

 State Pharmaceuticals Corporation hereby invite your C&F prices in USD for the supply of the item/s listed in the Annex I, which is for use in Government Medical Institutions.

TERMS AND CONDITIONS OF BID/INSTRUCTIONS TO BIDDERS

1. SUBMISSION OF BID.

- 1.1 Bid shall be submitted in one Original and One Duplicate sealed separately and marked as "Original " and "Duplicate" respectively. Both envelopes shall together be enclosed in one envelope sealed and addressed to 'Chairman/ Departmental Procurement Committee, State Pharmaceuticals Corporation of Sri Lanka, 16th Floor, "Mehewara Piyasa" 41, Kirula Road, Colombo 05 Sri Lanka.

Individual/separate bids to be submitted for each item

- 1.2 Bids, if sent through the Post, should be sent under registered cover. A Bidder may also personally deposit sealed Bids in the Tender Box provided for this purpose at Administration Department of the State Pharmaceuticals Corporation of Sri Lanka, 16th Floor, "Mehewara Piyasa" 41, Kirula Road, Colombo 05 Sri Lanka.

The left-hand top-corner of the envelopes should indicate the Bid Reference, **SR number of relevant item** and the closing date of Bid. Bids should be received on or before the closing date and time of Bid. Late Bids will not be entertained under any circumstances. The Corporation shall not accept responsibility for the Bid misplacement or premature opening of Bids if the envelopes have not been marked as given above.

2. FORMAT OF BID/ BID SUBMISSION FORM & PRICE SCHEDULE

- 02.1 Bids should be submitted according to the format given in **Annex IIA & IIB**.
- 02.2 Bids which are not in the prescribed format or are not in strict conformity with the terms, conditions and specifications laid-down in this Bid shall be rejected.
- 02.3 The Bid shall contain no interlineations, or even writing except as necessary to correct errors made by the Bidder - in which case such corrections shall be initialled by the person or persons signing the bid.
- 02.4 All Bids, literature etc., should be in the English Language.
- 02.5 The bid submitted should be duly signed and endorsed by the Bidder himself (the name and designation of the signatory, should be indicated)

VALIDITY OF OFFER

Bidders should keep their offers valid for acceptance for a period of at least 180 days from the date of closing of tender. No increase in price will be permitted after tender award.

3. ELIGIBLE GOODS AND REGISTRATION

- 4.1 WITH THE NATIONAL MEDICINES REGULATORY AUTHORITY (NMRA)
- (a) All Pharmaceutical Products imported to Sri Lanka should be registered with the National Medicines Regulatory Authority of Sri Lanka.
- (b) A Certified copy of the NMRA registration Certificate certified by Attorney-at-Law, Commissioner of Oaths or Justice of Peace should be submitted along with the bid.
- (c) All items shall be of Indian Origin**

5. FRESH STOCKS AND SHELF LIFE

- 5.1 Supplies should be conformed to the stipulated specifications and shelf life as stated in Annex 1. Residual shelf life should be at least 75% at the time of receipt of goods at MSD.
- 5.2 Corporation reserves the right to call for free replacement of goods supplied with inadequate residual shelf life, reimbursement the cost of goods or reject such deliveries.

6. COUNTRY OF ORIGIN AND NAME OF MANUFACTURER

The Country of Origin should be India and Name of Manufacturer should be indicated in the Bid Form at Annex II B.

7. BID OPENING

- 7.1 Bids will be opened immediately after closing, at the Head Office of the State Pharmaceuticals Corporation at 16th Floor, "Mehewara Piyasa" 41, Kirula Road, Colombo 05 Sri Lanka at the date and time specified in **Annex 1**.
- 7.2 The bidder or their authorized representatives will be permitted to be present at the opening of Bids.
- 7.3 Only the copy of the bid marked 'Original' will be opened at the time of opening of Bids.
- 7.4 The Bid Opening Committee who opens the bids will read out (or cause to be read out) to those present, the name of each Bidder as well as the amount quoted together with discounts, if any.

7.5 Any other detail which the Bid Opening Committee determines as necessary will be read out.

8. REIMBURSEMENT

- 8.1 Corporation reserves the right to call for reimbursement in the event of short packing, loss/damage or deterioration of goods supplied within the shelf-life, also for packs which cannot be identified due to labels falling off or items with incorrect labelling.
- 8.2. All quality problems/complaints should be confirmed by the National Medicines Regulatory Authority (NMRA)/ Technical Advisory Committee (TAC) of Sri Lanka/ SPC Quality Assurance Laboratory or any other Authority as decided by the Ministry of Health of Sri Lanka.
- a) In the event of receipt of a complaint samples will be tested by NMQAL, and follow the recall procedure approved by the Ministry of Health and will be destroyed according to section 72 of Drug regulations.
 - b) In case of withdrawals due to quality failure Suppliers should ensure that the value of entire quantity of either the withdrawn batches or products would be totally reimbursed with an additional 25% of the total value concerned as an Administrative Cost.

9. PERFORMANCE BOND

- 9.1 The successful Bidder shall within 07 days from the notification of award should submit an unconditional Performance Bond up to 25% of the total value of award and should be valid 3months beyond the last delivery date
- Failure to comply with this request shall constitute sufficient grounds for the Corporation to cancel such award .
- 9.2 However, the **Departmental Procurement Committee** reserves the Right to increase/decrease the required Performance Bond at their discretion.
- 9.3 The Performance Bond shall be as per specimen **Annexure IV** - and shall be issued by one of the institution given at para 5.2.
- 9.4 Claims on the Performance Bond will be made by the Corporation on the very first instance the supplier fails to comply with the terms and conditions of Bid or Purchase Order.

10. CONTRACT AND ARBITRATION

(A) CONTRACT

The successful supplier should agree to enter into a Contract/Agreement with the State Pharmaceuticals Corporation.

(B) ARBITRATION

If during the continuance of this Contract or at any time after the termination thereof, any difference or disputes which may arise between the parties hereto in regard to this interpretation of any of the provisions herein, contained or any other matter or thing relating to this contract (other than any difference or dispute in respect of which a decision of the Chairman of the State Pharmaceuticals Corporation of Sri Lanka, is declared to be final and

binding on the parties hereto) such difference or dispute shall be forthwith referred to an Arbitral Tribunal in Sri Lanka. Composition of the Arbitral Tribunal, Jurisdiction of the Arbitral Tribunal, Conduct of Arbitration Proceedings, awards and any other matters relating to the Arbitration shall abide by Arbitration Act No. 11 of 1995 of the Democratic Socialist Republic of Sri Lanka. The place of Arbitration shall be in Sri Lanka.

11. **PACKING AND STORAGE CONDITIONS**

- i. Pack Size offered should conform to requirements. Bids for alternate pack sizes may be rejected. Export-worthy packing which will prevent damage in transit should be used. Details of nature of packing should be given.
- ii. Packing of all items should be suitable for storage and use under tropical conditions. Final packing should indicate the required storage temperature for goods which require Refrigeration/ Cool Room/ Freezer Storage enabling the cargo handling staff to arrange proper storage for such goods immediately on receipt.
- iii. Containers and closures used should be of such quality so as not to react with the contents while in storage under tropical conditions.
- iv. Large tablets (over 250mg in weight) in bulk packs (over 500 tablets per pack) should not be packed in glass bottles as glass bottles are likely to be damaged in transit. Such items should be packed in sealed polyethylene film bags inserted in to strong airtight metal or plastic containers.
- v. Sri Lankan ambient storage conditions are in the ranges of 30°C +/- 2°C temperature and 75% +/-5% relative humidity.
- vii. The items which have to be stored between 2° C – 8° C should be delivered with cold chain monitors.
- viii. The Recommended storage mentioned on the Product label should be maintained at all levels including in transit and storage condition should be clearly shown on Invoice. All outer carton and inner box should contain the following information.
 - (a) Description of the Item
 - (b) Date of Manufacturer
 - (c) Date of Expiry
 - (d) Batch No.
 - (e) Name and Address of manufacturer

12. **LABELLING**

12.1 All labels should be printed in English Language and the labeling requirements should be according to the specifications required for registration at **NMRA** as follows.

- (a) The approved name found in official pharmacopoeias or formularies. (The source should be stated in abbreviations: e.g. BP, USP,...etc.)
- (b) The Brand Name
- (c) List of the active ingredients showing:
 - i. Amount of each presenting each dosage unit
 - ii. A Statements of the nett contents (e.g. number of dosage units, weight or volume)
- (d) Any special storage conditions that may be necessary
- (e) Warnings and precautions that may be necessary
- (f) The Date of Manufacture

- (g) The Date of expiry
- (h) The batch or lot number assigned by the manufacturer and
- (i) The name and Address of the manufacturer.

12.2 Anaesthetic Products

- (1) Generic Name of drug should be printed large and clear.
- (2) All ampoules should be effectively pre-cut.
- (3) Labels should be effectively pasted to avoid loosening when in contact with water. STICKER LABELS to be provided for Operating Theatre use.
- (4) Colour coding of sticker labels should be in accordance with the "Standard Specification for User Applied Drug Labels in **Anaesthesia**" set out by the American Society for Testing and Materials. ASTM D4774-88.

e.g. Relaxants	Red
Vasopressors	Violet
Opiates	Blue
Local Anaesthetics	Gray

Lignocaine with adrenaline and adrenaline ampoules should have a distinct red band and red lettering.

Sticker labels for syringes should be provided for the following drugs :-

Thiopentone	Pancuronium
Diazepam	Atracurium
Midazolam	Vacuronium
Ketamine	Neostigmine
Suxamethonium	Atropine
Tubarine	

13. PAYMENT

Will be arrange as per the terms and condition of Indian credit Line facility agreement with Government of Sri Lanka. Payment will be made in Indian Rupee equivalent to offer price in USD.

14. TENDER AWARD

Awards are made to suppliers taking into consideration among other factors, prices quoted, past performance, quality of samples, delivery offered, product registration etc. And the decision of the Procurement Committee is final.

The Procurement Committee reserves to itself the right without question to:-

- (a) Accept any bid, or portion of a bid,
- (b) Accept portions of more than one bid
- (c) Reject all or any bids
- (d) Direct that fresh bids be called for
- (e) Cancel the bid

The relevant **Procurement Committee** reserves the right, at time of award to decrease/increase the quantity required, by 25% without any change in price or other terms and conditions.

In case lowest evaluated responsive supplier is Bidding for a product which has not been supplied before, the relevant **Procurement Committee** reserves the right to purchase only

part quantity from such supplier and to get a feedback from the end users to decide on the balance quantity.

However, in such cases the price offered for the total amount should be maintained for the smaller quantity.

15. DELIVERY

Reference **Annex I** - Successful bidders should conform strictly to delivery dates. Failure to do so will result in forfeiture of the Performance Bond and/or cancellation of the award.

If awarded supplier is unable to adhere to the delivery schedule due to no fault of the SPC would result in the supplier being surcharged as per the condition mentioned under “condition of supply” in Annex I.

16. TESTING OF BATCH SAMPLES

- 16.1 In the case of distribution to Hospitals/ State Institutions random batch samples and random post-marketing samples of all goods supplied will be tested at the NMQAL/ Quality Assurance & Research Laboratory of the State Pharmaceuticals Corporation and reports on its suitability issued. The findings of the reports will be final and binding. Goods reported as unsuitable and not conforming to the laid down specifications will be rejected and subsequently destroyed. The suppliers should agree to refund its landed cost plus an additional 25% as an Administrative cost within 30 days from the date of intimation.

17. QUALITY CERTIFICATE

- (a) Corporation reserves the right to nominate Independent Competent Authorities for the issue of pre-shipment Certification (Certificate of Quality, Quantity and Loading). In such an event, the cost of **such certification** must be borne by the supplier and should be included in the Bid (**Annex 11B**).
- (b) The Secretary, Ministry of Health, Sri Lanka reserves the right to nominate suitable persons to inspect the production and quality control facilities of bidders and manufacturers and their records. Bidders, who refuse permission to our nominees to carry out such an audit will be automatically disqualified.
- (c) The expenses involved. In the inspections should be borne by the manufacturer/ supplier.

18. WHO CERTIFICATION SCHEME FOR QUALITY OF PHARMACEUTICAL PRODUCTS MOVING IN INTERNATIONAL COMMERCE

- (a) A certificate of Pharmaceutical Product (CPP) issued by the Competent Authority in the manufacturer’s country confirming that the item bided has been authorized to be placed in the market for sale and use in the country of manufacture, should be submitted along with the Bid.
- (a) The certificate of Pharmaceutical Product should also certify that the Manufacturing Plant in which the product is produced is subject to inspection at suitable intervals, and that the manufacturer conforms to the requirement for Good Practices in manufacture and quality control as recommended by the World Health Organization in respect of products to be sold or distributed within the country of origin or to be exported.
- (b) All batches offered should conform to the requirements of the Competent Authority for sale or distribution within the country of manufacture or where appropriate to published specifications, e.g. : BP/USP/IP or to established specifications provided by the manufacturer. These certificates should indicate the name and dosage form of the product, the batch number,

the date of manufacture, date of expiry, storage conditions, date of packaging, labeling, nature of the container, results of analysis and other data (BATCH CERTIFICATES).

19. PRODUCT LIABILITY

In the event of an order being placed, the supplier should indemnify the State Pharmaceuticals Corporation of Sri Lanka against all product liability claims arising out of the items supplied on his bid. E.g. due to incorrect labelling, deviation from agreed specifications etc.

1. PATENT RIGHTS (AND OTHER THIRD PARTY RIGHTS) AND ROYALTIES

The suppliers shall at all times indemnify and keep this Corporation indemnified against any and all claims arising at any time on Account of Patent rights or other rights, whether from manufacturers or others, from the use of the supplied goods in Sri Lanka.

21. BIDS FROM THOSE OTHER THAN MANUFACTURERS

Bids for supply of goods which are not manufactured by the bidder should be supported by a Certificate of Authority issued by the Manufacturer at the time of submitting bidding documents indicating that the bidder has been duly authorized to supply the goods bided for. Failure to comply will result in the offer being rejected.

22. TERMS & CONDITIONS AND CLARIFICATION

Prospective Bidders should acquaint themselves, fully with these terms and conditions and if any further clarification is required please contact the undersigned, No plea of lack of information or insufficient information will be entertained at any stage.

23. EXAMINATION, EVALUATION AND COMPARISON OF OFFERS

23.1 The purpose of bid evaluation is to determine the lowest evaluated bid from the substantially responsive bids received.

i) Preliminary examination

The Bid received will be examined by the Technical Evaluation Committee appointed for each bid to determine whether they are complete, whether they are from eligible bidders, whether the document has been properly signed, whether any computational errors and whether the samples are provided if required and whether the specimen Bid form at **Annex 11 (A)** has been followed and the price schedule as per **Annex 11 (B)** has been followed.

ii) Prior to detailed evaluation

The TEC will determine the substantial responsiveness of each offer to the bidding documents as pursuant to clause 26.1.(i). A substantially responsive bid is one, which conform to all the conditions described in clause 26.1 (i) without any deviation. A bid determined as not substantially responsive will be rejected and may not subsequently be made responsive by the bidder by correction of the non-conformity.

The offers, which are previously determined to be substantially responsive to clauses.

23.2 (i), (ii) will be further evaluated.

iii) The TEC and the Corporation will also examine the Bids in order to ensure the correctness of the Bids. Arithmetical errors, if any, will be corrected on the following basis;

- a) If Discrepancy is between Unit Price and Total Price, then the Unit Price shall prevail and the Total Price will be corrected.

- b) If Discrepancy is between words and figures, the amount in words will prevail.
 - c) If a Discrepancy appears between the original bid and the duplicate, the original will prevail.
- iv) All the items offered in Annex 11B should conform strictly to the technical specifications set out in the Annex 1 of this document and will be taken in to account at the time of evaluation.
- Unless specifically stated in this document any other relevant Terms & Conditions of Bid/Instructions to Bidders any annexures mentioned in 'Global Bid Document Pharmaceutical DPC' available for perusal at web site of SPC, Home page, main menu under the Tab 'Tenders' in www.spc.lk and Guide Lines for Procurement of Pharmaceuticals issued by the Government with its subsequent amendments/revisions will be applicable.
 - In the event of conflict between Global Bid Document Pharmaceutical DPC, Procurement Guide Line for Procurement of Pharmaceuticals and Medical Devices Procurement Guide Lines issued by the Government 2006, and subsequent Amendments/Supplements this 'Bidding Document for Invitation of Restricted Bids' shall prevail.

Abbreviations : SPC ; State *Pharmaceuticals Corporation, MSD; Medical Supplies Division.*

Yours faithfully

STATE PHARMACEUTICALS CORPORATION OF SRI LANKA

**PROCUREMENT OFFICER
DHS - [PHARMACEUTICALS]**

Telephone : (00) 94- 11 - 2582509

Fax : (00) 94 – 11 – 2582496

E-MAIL address: dgmpharma@spc.lk and pharma.manager@spc.lk

CC :

ANNEX I

BID NO./BID REFERENCE : DHS/ICL/X/008/2022

Closing on : 31.03.2022 at 09.00 am

SR No.	Item Description/Specifications	Quantity	Delivery Schedule
	AS LISTED BELOW		

Sufficient quantity of Representative samples for the item to be submitted for the evaluation as tender samples.

Bid validity period : Bid should be valid till 27.09.2022 [180 days of tender closing]

Bid Evaluation Summary sheet should be submitted with the Bid (Please refer SPC website for more details)

MSD CONDITIONS OF SUPPLY

1. The consignments supplied in respect of an order concerned, shall exactly match with the reference sample submitted and the product information (item descriptions, shelf life/warranty where applicable, manufacturer's name, country of manufacture, country of origin, etc.) provided in the bid document by the supplier, which has been accepted by the procurement committee, and included in the Indent / Purchase Order (PO), issued by SPC.
2. All items shall be supplied, sourcing from the manufacturer and country of manufacturer, stated in the Purchase Order (PO)/Indent of SPC and wherever applicable shall have a valid product registration or waiver of registration from NMRA.
3. Maintaining the validity of the product registration during the period of supply(delivery schedule), obtaining waiver of registration &/ import license / manufacture licensing at NMRA, is a pre-requisite for the supply of surgical, pharmaceutical and relevant laboratory items. Hence all suppliers shall produce relevant valid registration certificates/licenses, when requested by MSD/SPC.

When the validity of the product/manufacturing licenses and registrations of NMRA (eg; manufacturing license, product registration and GMP certificates), of local manufacturers / local suppliers, lapses during the year or during the period of supply (delivery schedule), it shall be

extended / renewed by the supplier. A certified copies of afore mentioned valid certificates shall be submitted to MSD by the supplier when deliveries are made.

4. If MSD decides to accept a part or full consignment, with deviations from certain tender conditions (eg: with regard to labeling/packaging etc.) due to an urgency, that shall be done subject to, either rectifying the defect within 05 working days by the supplier, or recovering the total cost [a] of rectifying the defect by MSD (via a duly contracted third party providing such services), from the supplier with a 25% surcharge on the labeling cost. (total charge = [a]+[a]x0.25) or 2% of the invoiced value, whichever is the highest.
5. The specifications of the product offered in the bid, by the supplier shall match with the tender specifications for the item and any form of alternate offers will not be entertained.

Shelf life & Warrantees

6. Freshly manufactured stocks of the product shall be supplied; thereby the residual Shelf Life (shelf life remaining at the time of delivery of goods in Sri Lanka/MSD stores in case of local supplies) of the product, shall be 75% of the shelf life requested (specified in order/Indent/PO).
In respect of the items with requested shelf life equal or more than 24 months, any deficit between the residual shelf life and requested shelf, shall not be more than 04 months.

In the violation of the above tender condition, SPC/MSD reserves the right to accept a reduced quantity, that is usable (as per the consumption rate) up to three months before the expiry of same and will subject to application of a penalty (as clause No. 28).

When the shelf life is not specified in the indent/PO/item spec; the requested shelf life shall be considered as, 36 months for surgical items and 24 months for pharma. / laboratory items.

Standards & Quality

7. **Standards;** In addition to Pharmacopoeial Standards that are indicated in the item specifications, other Pharmacopoeial Standards that are registered at National Medicines Regulatory Authority in Sri Lanka are also acceptable when no bidders have quoted for the standard specified in the item specification.
8. Any product deficient of its sub components/ accessories, not at the specified quality standards or all its components not unitized appropriately in packaging (as a set), shall be rejected.
9. Withdrawal from use of items due to quality failure found as manufacturer's fault:
 - (a). In case of batch withdrawal, **value of entire batch quantity supplied** shall be recovered from the supplier.
 - (b). In case of product withdrawal, **value of entire product quantity** supplied shall be recovered from the supplier.
 - (c). In the event of either a) or b) above, supplier shall be surcharged the total **cost involved for MSD, of the quality failed supplies** with 25% administrative surcharge of the same.
10. The storage conditions and the packing requirements of the product shall conform to the information given by the manufacturer and accepted by NMRA for the product registration or shall conform to the information submitted for waiver of registration granted by NMRA in exceptional circumstances. (refer clause No.17)
If the offered product, deviate from NMRA registered product features, supplier must provide with the bid, a declaration to certify the NMRA accepted product details such as; storage conditions, pack details/contents/sizes and standard batch quantity/size of the product.

11. Immediately after delivery at MSD, the consignments shall be subjected to testing appropriately drawn, one random batch sample (Post-delivery sample) of the consignment at a government/semi-government/accredited laboratory.(to be selectively applied for Surgical & Lab items, depending on availability of testing methodology & facilities) If the sample is found to be substandard, random batch samples will be tested from all the batches/ lots in the consignment, and entire expenses on such tests, like value of samples, transport, sampling & testing charges, etc, will be recovered from the supplier.

12. Consignments supplied to MSD violating the storage conditions indicated on product labels and/or product information leaflet (as accepted for product registration at NMRA), shall be considered as quality affected consignments and quality assurance of such consignments shall be carried out by post-delivery testing at government / semi government laboratory in Sri Lanka or at an accredited laboratory (foreign/local). All the expenses on such an event, including storage cost shall be borne by the supplier. If found to be quality affected the consignment will be treated as quality failed (as clause No.09).

Pack size, Labeling & Packaging

13. Offers for pack sizes at a lower level(smaller quantity per pack) than the pack size specified in the item description/specification and MSD order List, are also acceptable, but higher level (larger quantity per pack) pack sizes will not be entertained unless otherwise offered with the original bid and accepted by the procurement committee, with the concurrence of MSD.

14. Description of the Item, Date of Manufacture, Date of Expiry, Batch No, Name and address of manufacturer shall be clearly marked on the outer covering of the individual/innermost pack containing the minimum unit of measure, including blister & strip cards and on the outer cover of the carton/box. Any deviations of the Date of Manufacture (DOM)/ Date of Expiry(DOE)declared in the offer shall be approved by MSD and DOM & DOE shall consist of at least the year & month.

15. All outer most cartons (shipping packages) shall bear the Batch No, and Date of Expiry in size 1.5cm letters / figures in prominently visible manner. This may be printed, stenciled or label properly affixed.

16. In case of receiving goods under inappropriate packaging conditions(not in good order), was to be sorted out by MSD to select the items in good order by 100% checking/handling of the consignment, all expenses incurred to MSD in such an event (including demurrage charges, cold stores charges, labor charges etc. or any other charges incurred until goods are ready for acceptance), have to be paid to MSD by the local supplier, before attending to checking the consignment 100%, by MSD.

In respect of SPC imported supplies, if the local agent does not follow suit as above, such extra expenses incurred to MSD shall be recovered from the supplier by SPC and refund to MSD.

Storage Conditions & Temperature

17. If the storage temperature & conditions are not specified in the item specification, NMRA accepted product storage conditions, shall conform to Sri Lankan ambient storage conditions in the ranges of 30^oc +/- 2^oc temperature and 75% +/-5% relative humidity. The product storage conditions shall be clearly indicated at all levels of labels/packages/boxes.

Maintenance of Cold Chain;

a.In case of cold storage items, cold chain monitors (temperature recording devices) shall be included for each carton and the cold chain shall be maintained according to the manufacturer's instructions during storage, transport and delivery.

- b. Supplier shall use suitable prominently visible identification marks of international standard, with appropriate colours and sizes for easy identification of cold cargo. Supplier shall use standardized **USB Devices** for temperature data logging inside the packages and shall provide free of charge, data logger readers **&/ software (reading apps compatible with Windows-07/latest)** to wharf department of SPC in advance, to enable examining the maintenance of cold chain in transit, and before taking over the consignment by MSD.
- c. If the cold chain break is observed at the time of taking over the consignments by MSD, such consignments shall be rejected, indicating the reason on the relevant **WDN or copy of the delivery documents**. In such an event, the SPC shall arrange necessary cold storage for the consignment until 'observed cold chain break' is investigated leading to acceptance / total rejection of consignment and the expenses born by MSD / SPC in arranging the cold storage shall be recovered from the supplier.
- d. The vehicles transporting cold cargo to MSD shall be equipped with temperature monitoring devices and the vehicle shall have NMRA approval for transport of pharmaceuticals.
- e. The suppliers shall dispatch consignments of the items, which require cold chain maintenance, to arrive in Sri Lanka during Monday to Thursday to avoid additional demurrage & storage charges during weekends, during which MSD stores is closed. In case of non-compliance of this condition, any additional expenses incurred to MSD and SPC, to Custom clear/store/receive such consignments shall be recovered from the supplier.
18. In respect of the products requiring controlled temperature storage (Eg. < 25^oc, 2-25^oc, 15-20^oc/30^oc, 2-8^oc etc.), supplier shall provide MSD with latest product stability study reports with the invoice of the consignment. (report shall include studies; at 30^oc +/- 2^oc & 75% +/- 5% RH for **AC stored** items and at 25^oc +/- 2^oc & 60% +/- 5% RH for **Cold stored** items. It shall be a true copy of the latest report submitted to NMRA or a report issued within last 05 years).

Delivery Requirements

19. All items shall be supplied as per the latest/final delivery schedule, communicated to the supplier, as an amended Indent/PO delivery schedule (if not amended, original schedule in the Indent/PO will apply) mutually agreed between MSD& SPC, at the time of establishing the payment terms (L/C, DP, TT, etc). Any deviation from this agreed delivery schedule shall be treated as a defaulted delivery.

Contravening the above directions, if the delivery schedule is violated by the supplier for no fault of MSD/SPC/MOH and in the event MSD decides to accept any such consignment in full or part thereof, that is delivered after the due delivery date, Condition No. 21 on delayed deliveries, shall be applied.

20. All consignments shall be delivered at Medical Supplies Division or an alternate receiving point as directed.

21. Defaulted consignments with respect to delivery schedule shall only be considered for acceptance, subject to a penalty imposed for the delay due to suppliers fault, allowing a grace period up to two weeks. Consignments delivered after that grace period shall be considered for acceptance subject to a penalty ⁸ to the supplier as described below ;

(a). A penalty of 0.5% per day of the consignment value, calculated commencing from the 15th day up to 60th day delay from the due delivery date, as per the indent/PO or its' latest amended delivery schedules.

(b). When the delay exceeds 60days purchase order will be considered as automatically cancelled, on defaulted performance. In such a situation, MSD reserve the right to recover liquidated

damages or to revoke the cancellation (eg. if payments have been released prior to such a cancellation), and accept the consignment subject to a 25% admin surcharge.

22. The extension of L/C's overstepping delivery schedules in the Indent/PO/its' amendments, shall not in any way affect the recovery of late delivery charges, as per Condition No. 21 (regarding defaulted consignments) and any other direct or indirect additional costs/liquidated damages, relating/consequent to extension of L/C

23. When adequate storage space is not available at MSD, to accept a delivery defaulted consignment (deviating from the delivery schedule in the Indent/PO/its' amendments) under the condition No. 21, any additional expenses caused to MSD or SPC in arranging temporary external storage and other expenses (eg. demurrage, detention, container storage, re-handling cum transport, etc.) shall be borne by the supplier.

Documents & Information

24. MSD Order No, Item Description, SR No, Batch No., Date of Manufacture, Date of Expiry and product Storage Condition, shall be indicated in all Supply Invoices and detailed Packing Lists.

25. The supplier shall submit all shipping documents to (Including Bills of Lading / Draft Air Way Bills etc.) SPC Imports department and MSD by e-mail (**follow instructions in website www.msd.gov.lk**), at least 03 days before the Expected Time of Arrival (ETA) of sea freighted consignments & 02 days before the ETA of Air freighted consignments.

26. If it is not complied or the information so provided are found to be incomplete/false, the grace period (for supply delays) mentioned in the clause 21 will not be applicable.

All the documents listed as a requirement or Indian Credit Line facility should be provided soon after intimation of the order. Documents required is listed and annex as annexures and Form A,B,C,D,E and Excel sheet.

Common conditions

27. In addition to the general conditions of supply given herein, item/order-list specific amendments, exclusions or additions to the same, stated in the covering letter of the order list and any other relevant conditions as per the tender document issued by SPC, are also applicable. The order/item specific; new conditions or amendments to General Order Conditions, will be included in the order list itself and as a remark entry in the MSMIS order records.

28. Administrative surcharge of 25%(on the value of goods), will be applied for tender condition violations that cause deficiencies in supply with respect to; quality, standards & specifications, short packing & short supply or delayed delivery as per the cabinet decision.

Abbreviations :NMRA ; *National Medicines Regulatory Authority/Sri Lanka*, SPC ; *State Pharmaceuticals Corporation*, MSD; *Medical Supplies Division/Ministry of Health-Sri Lanka*.

SPECIMEN FORM OF BID (SUPPLIES)

Chairman,
Departmental Procurement Committee
.....
.....

<p>BID FOR THE SUPPLY OF</p> <p>.....</p> <p>BID NO./BID REFERENCE</p>
--

1. I/ We, the undersigned, having read and fully acquainted myself/ourselves with the contents of the Terms and Conditions of Bid/Instructions to Bidders and Contract and Annex I where specifications and delivery of items required pertaining to the above Bid, hereby undertake to supply the goods referred to therein, in accordance with the aforesaid Instructions, Terms and Conditions as per price quoted in the attached Annex II B.

2. I/ We confirm that this offer shall be open for acceptance until..... and that it will not be withdrawn or revoked prior to that date.

3. I/We attach hereto the following documents as part of my/our Bid:

- (I) Price schedules (as per Annex II B – Bid Form
- (II) Documentary evidence to establish Registration of product with the National Medicines Regulatory Authority Certificate No
- (III) Documentary evidence to establish that goods offered are from an eligible source and

origin.

(Document as required in Para. 4 of the Terms & conditions of the Bid).

(IV) Any other documents (give details).

4. I/We understand that you are not bound to accept the lowest bid and that you reserve the right to reject any or all Bids or to accept any part of a Bid without assigning any reasons thereof.

5. We undertake to adhere to the Delivery Schedule indicated.

6. My/Our Bank Reference is as follows:
.....

Signature:

Name of Bidder :

Address:

E-mail:

Telex -

Fax:

Date

STATE PHARMACEUTICALS CORPORATION – BID FORM

ANNEX 11 (B)

(To be submitted in duplicate)

BID NO./BID REFERENCE.....

CLOSING ON:

NAME & ADDRESS OF MANUFACTURER :

NAME & ADDRESS OF BIDDER :

(Bidders should prepare their own forms as per this format. Offers which are not as per the format are liable to be rejected)

1	2	3	4	5	6	7	8	9	10
SR NO./ITEM NO.	FULL DESCRIPTION OF ITEM OFFERED, THE STANDARD AND THE STORAGE TEMPERATURE	PACK SIZE OFFERED	QTY OFFERED	PROBABLE SHIPMENT/DELIVERY DATE	UNIT PRICE C&F (USD)	TOTAL PRICE C&F (USD)	NMRA REGISTRATION CERTIFICATE NO. & DATE OF EXPIRY	SHELF LIFE	COUNTRY OF ORIGIN

1. Cost of Inspection Certificate (If not included in the unit delivered price).....
Indicate from whom independent Pre-shipment Certificate of Quality, Quantity and Loading will be submitted.
2. Indicate date when samples were submitted:-
3. Quotation Valid upto :-.....

We confirm that we have read and understood the terms, conditions and specifications covering this tender and submitted our offer accordingly. We are not listed as defaulted/ black-listed Bidder in any Government Institution in Sri Lanka. "In the event of goods being rejected due to un-acceptable quality, reimbursement of its value and an additional 25% of the total value at landed cost as an administrative charge will be made".

Name of Bidder :

Signature of Bidder :
(With Name and Designation of Signatory)

Official Stamp of Bidder :

Postal Address of Bidder :

Telephone No. :

E-mail :

Fax No. :

Name of Bankers with Account No.

Beneficiary :

(Inform your terms and conditions and special instructions for opening Letters of Credit in the event of an award in your favour) _____.

NOTE

1.Storage temperature of the offered items should be prominently indicated in the column No. 2.

**SPECIMEN FORM OF PERFORMANCE BANK GUARANTEE
(UNCONDITIONAL)**

BOND NUMBER: **DATE:**

SUM GUARANTEED:

To:..... (Name of employer)

..... (Address of employer)

Whereasname and address of contractor)
(hereinafter called "the contractor") has undertaken, in persuance of contract No..... dated
to execute(name of contract) (hereinafter called "the contract");

And whereas it has been stipulated by you in the said Contract that the Contractor shall furnish you with a Bank Guarantee by a recognised Bank for the sum specified therein as security for compliance with his obligations in accordance with the Contract;

And whereas we have agreed to give the Contractor such a Bank Guarantee;

Now therefore we hereby affirm that we are the Guarantor and responsible to you, on behalf of the Contractor, up to a total of (amount of Guarantee)
..... (amount in words), such sum being payable in the type and proportions of currencies in which the Contract Price is payable, and we undertake to pay you, upon your first written demand and without cavil or argument, any sum or sums within the limits of (amount of Guarantee) as aforesaid without your needing to prove or to show grounds or reasons for your demand for the sum specified therein.

We hereby waive the necessity of your demanding the said debt from the contractor before presenting us with the demand.

We further agree that no change or addition to or other modification of the terms of the Contract or of the Works to be performed thereunder or of any of the Contract document which may be made between you and the Contractor shall in any way release us from any liability under this guarantee, and We hereby waive notice or any such change, addition or modification.

This guarantee shall be valid until a date 28 days from the date of issue of the taking over Certificate.

Signature and the Seal of the Guarantor:

Name of the Bank:

Address

Date:

Witness :

Sea/Air

DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA

Our Ref No. :

Date :

Tender No :

This AGREEMENT made and entered into between the State Pharmaceuticals Corporation having the Registered office at 16th Floor, “Mehewara Piyasa”, 41, Kiur;a Road, Colombo 05, Sri Lanka (hereinafter called the “SPC” which term or expression shall mean and include the said State Pharmaceuticals Corporation and its successors and permitted assigns) of the One Part and M/s. business under the time, style and firm of a company duly registered and carrying business (hereinafter called “the supplier” and which term or expression shall mean and include the said and its/their/its heirs executors administrator and permitted assign/successors in business or permitted assigns) of the Other – Part.

Whereas the State Pharmaceuticals Corporation has accepted the tender of M/s. for the supply and delivery of in the manner and quantities as per the attached Indent for USD marked hereof.

NOW IT IS HEREBY AGREED AS FOLLOWS:

- 1. The following documents: -**
 - (a) Conditions of contract marked 1**
 - (b) Bid documents marked 2**
 - (c) Copy of Indent marked 3**

(hereinafter called “the Contract Documents”) showing and describing the nature and scope of the Agreement duly signed by both parties shall be deemed to form and be read and construed as part and parcel of this Agreement.

- 2. In consideration of the payment to be made by SPC to the supplier the contract sum hereinafter mentioned the supplier hereby covenants with SPC to supply and deliver the goods in conformity in all respects with the provisions of this contract.**

The supplier shall be paid for such supply and delivery of the goods according to the Indent No. -----marked 3 and in the manner and at the times hereinafter specified.

This contract as herein before defined constitutes the entire agreement between SPC and the supplier and may only be modified or repealed by formal agreement in writing duly executed by the parties or their authorized representatives.

In witness whereof the official Seal to be affixed and the signature of the Authorized officers of the State Pharmaceuticals Corporation of Sri Lanka have set their hands and Suppliers has placed its hand/ caused its Common Seal to be affixed hereunto and to two other of the same tenor on this

The Common Seal of M/s. herein.

1.
President/Managing Director/C.E.O.

2.
Director

Witnesses

Signature

Name, Address and ID No.

1.

2.

CONDITIONS OF CONTRACT

1. SCOPE OF CONTRACT

Provide Pharmaceuticals for the Department of Health Services as per The Tender No. ----- closed on hereof.

2. GOODS

- 2.1 Supply should be from fresh stocks of recent manufacture conforming to the stipulations in the schedule marked 3 and the samples submitted.**
- 2.2 The goods supplied should have at least ... month's residual shelf life at the time of receipt in Sri Lanka**
- 2.3 Goods supplied should meet the Dissolution Bio equivalence test requirements where applicable.**
- 2.4 SPC reserves the right to: -**
- (a) Reject goods supplied with an inadequate shelf life and refrain from clearance from port or,**
 - (b) Call for free replacement of goods or reimbursement of cost so supplied, which do not conform to required standards.**

3 FREE REPLACEMENT AND /OR REIMBURSEMENT DUE TO QUALITY ISSUE

3.1 SPC reserves the right to call for the replacement or reimbursement in the event of

- 3.1.1 Short packing**
- 3.1.2. Loss damage or deterioration of goods supplied (within Shelf Life)**
- 3.1.3. Packs which cannot be identified due to labels falling off.**
- 3.1.4. Goods supplied fails to perform or meet requirements of the specification to the satisfaction of SPC. (Quality/Standard)**

- 3.2** In the event of quality problem, Batch samples would be tested by SPC/its authorized personnel at the NMQUAL or its fitness for use will be determined by an expert committee appointed by the relevant Authority.

Samples from the available batches will be retained by SPC and the balance will be destroyed by authorized officers in the presence of Local Agent and a certificate of destruction issued by SPC following destruction.

In case of Batch/Product withdrawals due to quality failure the supplier should reimburse SPC the total value of the entire quantity of either withdrawn batches of withdrawn product with an additional 25% of the total value concerned as an Administrative Cost.

- 3.3** Withdrawal from use of items due to quality failure found as manufacturer's fault.

- (a) In case of batch withdrawal, value of entire batch quantity supplied shall be recovered from the supplier.**
- (b) In case of product withdrawal, value of entire product quantity supplied shall be recovered⁸ from the supplier.**
- (c) In the event of either a) or b) above supplier shall be surcharged⁸ the total cost involved for MSD, of the quality failed supplier with 25% administrative surcharge of the same.**

4 VARIATION

The SPC may at the time of Award increase or decrease the order by up to 25% without being subject to any change in price or terms and conditions hereof.

5 PACKING AND STORAGE

- 5.1 Packing of all items should be suitable for storage and use under tropical conditions and sufficient marking should be made on the cases or containers in order to prevent possible mistakes regarding proper storage during transit, particularly for items requiring refrigeration or cool storage.
- 5.2 Containers and closures used should be of such quality so as not to react with the contents while in storage under tropical conditions.
- 5.3 Deleted.
- 5.4 Export packing should be in seaworthy strong cases or cartons to prevent damage in transit and should:-
- 5.4.1 Indicate recommended storage temperature for goods which require cool/cold or freezer storage.
 - 5.4.2 Stenciled with red bands in the form of a cross on each face.
 - 5.4.3 Carry shipping marks – details provided by SPC with order.
 - 5.4.4 Be palletized and shrink wrapped if it is Bag Cargo.
 - 5.4.5 Should carry Batch No./Exp. Date.
- 5.5 Approved packing material as per bid document should be used. Use of Rice Straw or other vegetable matter as packing is strictly prohibited (as per regulations passed under the Plant Protection Ordinance Chapter 447). In the event of such material being used extra costs incurred by SPC by way of fumigation charges, penalty rates, demurrage etc., in clearing such consignment from the port would be debited and payable as extra costs by the supplier.

6. LABELLING

- 6.1 All labels should be printed in English Language and the labeling requirements should be according to the specifications required for registration at NMRA as follows.
- a) The approved name found in official pharmacopoeias or formularies. (The source should be stated in abbreviations; e.g. BP or USP etc...)
 - b) The brand name
 - c) List of the active ingredients showing;
 - a) The amount of each present in each dosage unit (e.g. per 5ml etc...)
 - b) A statement of the net contents (e.g. number of dosage units, weight or volume)
 - d) Any special storage conditions that may be necessary
 - e) Warning and precautions that may be necessary
 - f) The Date of manufacture
 - g) The Date of expiry where applicable

- h) The batch or lot number assigned by the manufacturer and
- i) The Name and address of manufacturer
- j) Name and address of supplier, if supplier is not the manufacturer

6.2 Size of the letters of the above (f), (g), (h) and the SR Number on the outer carton should not be less than 1.5 cm.

6.3 Labeling of the products ordered under this range of indents, in addition to the labeling requirements stipulated in the BP/USP relevant standards, should also bear the State Logo.

6.4 Deleted

6.5 Deleted

7. IDENTIFICATION MARKS

The “State Mark” and “SR NO” made available by SPC should be embossed or imprinted in each (item) ampoule/ vial/ pack or on the affixed label. These marks should be indelible.

8. TERMS OF DELIVERY (Sea/Air freight)

8.1 All shipments should be made exclusively on vessels belonging to the Ceylon shipping Corporation or those chartered by CSC. Shipments on other vessels will be permitted in instances where vessel of the Ceylon Shipping Corporation do not call at the Port of shipment or if they are not available for time by shipment of cargo, in which event the supplier should attached a waiver certificate issued by Ceylon Shipping Corporation or their Authorized Agent in the Supplier’s Country.

8.2 SPC may nominate Independent Competent Authorities for issue of shipment Certificate (Certificate of Quality, Quantity and Loading) cost of such certificate should be borne by the supplier

8.3 All items should be shipped to the destination and strictly conform to the delivery dates as per schedule I hereto marked -----.

8.4 If the supplier fails to make deliveries within the time specified by the SPC (without prejudice to the other rights of SPC resulting from breach of the contract conditions) May be written notice to the supplier terminate the right of the supplier to proceed with any or all of the remaining part of the contract as provided for in clause 9.1 hereof in addition the SPC reserves the right to purchase from other sources any or all undelivered items and to recover excess costs from the supplier.

8.5 Deleted

8.6 Delivery of all goods should be within the period indicated in the Indent, except in exceptional circumstances no extensions will be granted. Cost of such extension in any would be borne by the supplier.

9. PAYMENT

Payment will be arrange as per the terms and condition of Indian credit Line facility agreement with Government of Sri Lanka. Payment will be made in Indian Rupee equivalent to offer price in USD.

10. PERFORMANCE BOND

10.1 As security for the due and punctual performance and fulfillment of the terms of this Agreement by the satisfactory completion of the supply and delivery, for the payment of all claims to which SPC may be entitled under the provisions of this Agreement. The supplier has furnished the State Pharmaceuticals Corporation with a Bank Guarantee from a Bank approved by the SPC in the sum of United States Dollars only. (USD)

11. ARBITRATION

- 11.1. If any dispute or difference or claim shall arise between the parties as to any point in any agreement or contract arising of the invitation to Bid, or as to any matter or thing of whatsoever nature arising there-under or in connection therewith, then either party shall within 30 days give to the other, notice in writing of such dispute or difference. Such notice shall specify the matters which are in dispute. Such dispute shall be referred to a single arbitrator in case the parties agree upon one; otherwise to three arbitrators; one to be appointed by each party and the third arbitrator by the other two arbitrators. If either party shall refuse or neglect to appoint an arbitrator within twenty days after the other party shall have appointed an arbitrator and given notice thereof requiring such appointment, then the arbitrator appointed as aforesaid shall proceed to hear and determine the matters as if he were and arbitrator appointed by both parties to the dispute.
- 11.2. The decision or award of the arbitrator or arbitrators (as the case may be) shall be final and binding upon the parties and shall be a prerequisite to any proceedings in a Court of Law.
- 11.3. The arbitrator or arbitrators shall determine by whom, and in what manner, the cost of arbitration (or any party thereof) shall be borne and paid.
- 11.4. The arbitration shall be governed by the Arbitration Act. No. 11 of 1995 Laws of Sri Lanka and shall be held in Sri Lanka.

11.5. Performance of the contract shall continue during arbitration proceedings as far as possible.

12. LAW

12.1. The Laws of the Democratic Socialist Republic of Sri Lanka shall govern the validity, performance and enforcement of this contract.

13. INDEMNITY

13.1. The supplier shall at all times keep indemnified the SPC against any and all claims at any time arising on account of -

(a) Patent right or other rights whether from manufacturer or others, from use in Sri Lanka of the goods supplied.

(b) Product liability claims against SPC arising out of the goods supplied under this contract e.g. due to incorrect labeling, deviation from agreed specifications etc.

14. WARRANTY

14.1. The supplier warrants that goods supplied shall be of recent manufacture and of good quality; shall have no defect in manufacture, shall meet all the requirements of the specifications and shall in all aspects suited for the purposes intended the warranty provided by the supplier shall be relied upon and strictly enforced by SPC.

15. WARRANTY AGAINST BENEFITS

15.1. The supplier warrants that he/it has not given or promised to give any money or gift to any officer or employee of SPC or any Government instrumentality or employee thereof with the intent or objective of securing the contract.

15.2. Any violation of this warranty shall be sufficient grounds for cancellation or revocation of the contract without any claim against SPC.

16. LOCAL AGENT

15.1 Name & Address : M/s.

Telephone No :

E-mail :

Fax No :

17. ASSIGNMENT

17.1. Supplier shall not without the prior written consent of the SPC assign his contract or part thereof to another.

18.Deleted.

19.FORCE MAJEURE

19.1. The supplier shall not be liable for any delay or failure in making delivery of the supplies if it was due to any event which interfered with performance and was beyond the control of the supplier. However, at every time the supplier faces a situation disturbing the due performance of the obligations under this contract due to conditions beyond his/ its control he/it should write to SPC and get its approval. Approval/disapproval will be notified within Seven (7) working days of receipt of same in writing. Parties however shall endeavors to remove any obstacles to performance (when possible) and co-operate to remove the harmful effects as far as practicable.

20.NOTICE

20.1.All notices given in respect of this contract shall be deemed to be sufficiently given if sent by registered post addressed to the either party at the respective address` at the beginning hereof written.

INDENT NO :

ITEM :

SUPPLIER : M/s.

In witness whereof the official Seal and the signature of the Authorized officers of the State Pharmaceuticals Corporation of Sri Lanka was affixed hereto namely-----.

DEPUTY GENERAL MANAGER / AUTHORIZED OFFICER

(PROCUREMENT & IMPORTS – PHARMACEUTICALS)

MANAGER (IMPORTS / AUTHORIZED OFFICER – PHARMACETIUCALS

Witnesses

Signature

Name, Address and ID No.

1.

.....

2.

.....

Form A

Supportive documents to be submitted with the Performa Invoice.

The following documents should be submitted by the importer with respect to the prospective exporter in India.

	Description	Remarks
01	Nature of entity: Company/ Proprietorship firm/ Others;	Specify here
02	Certificate of Incorporation (or equivalent documents of constitution or association), and/or documents of registration;	Certified by company secretary/ a director/ partner/ lawyer.
03	IEC, PAN and GST Registration details (Copies);	Certified by company secretary/ a director/ partner/ a lawyer.
04	List of Board of Directors with their complete designation in case of nominee Directors;	Certified by company secretary
05	The beneficial ownership with respective shareholding and nationality of shareholders of the JV Member (in case of a JV);	Certified by the company secretary or a director
06	A copy (self-attested on all pages) of Power of Attorney in favour of the person who has been authorised, through an appropriate Company Board Resolution or equivalent document, to sign on behalf of the Applicant;	Certified by the company secretary/ a director/ a partner/ a lawyer.
07	Financial Status & Capacity, certified by the Statutory Auditors of the company/firm;	
08	In case of JV, Applicant's JV Member's Information (in the format attached);	Attach duly filled form "C"
09	Details of non-performed export contracts, if any;	Specify details
10	Copy of necessary Certificates regarding safety from relevant agencies in India such as Food Safety and Standards Authority of India (FSSAI) in case of food items; Drugs Controller General of India (DCGI) in case of medicines etc, wherever applicable;	Certified by the company secretary/ a director/ a partner/ a lawyer.
11	Details, as mentioned in the attached questionnaire;	Attach duly filled form "B"
12	Declaration / Affidavit to the effect that all the information provided in the prescribed format is correct and in case any figures or information given therein are found to be incorrect and/ or certificates/documents provided in support of the relevant information entered therein are found to be fabricated, the contract will not be considered for inclusion under the credit facility (in the	Attach duly filled form "E"

	format attached).	
13	Agreement on Receiving Payments in Indian Rupees (INR) by the Indian Exporter's Bank	Attach duly filled form "D"

Form B

Format of questionnaire

S.No.	Information sought	Response
1.	Has your firm been suspended or debarred by any Multilateral Agency, or any government or government procuring entity, or a UN agency? If Yes, provide details, including date of reinstatement, if applicable. Attach additional sheets, if needed.	Yes/No
2.	Has your firm's account been classified as Non-Performing Asset (NPA) with any Bank/FI or your companies/ promoters/ directors appear in Reserve Bank of India (RBI) Caution List, RBI Wilful Defaulter List (Suit filed as well as non-suit filed), Credit Information Bureau India Ltd (CIBIL) Defaulter List or any other negative list of the Indian central or state government agencies, updated from time to time? If yes, please provide details in a separate sheet, as necessary.	Yes/No
3.	Has your firm/organization ever filed or petitioned for bankruptcy? If Yes, furnish details of the case including filing date and current status.	Yes/No
4.	Has your firm/ any JV partner been penalized for delay in contractual performance in the last 5 years prior to Application submission deadline. If yes, please provide details in a separate sheet, as necessary.	Yes/No
5.	Has there been a termination of your contract for nonperformance in the last 5 years prior to the month preceding the month of Application Submission Deadline? If yes, please describe in detail in a separate sheet, as necessary.	Yes/No
6.	Is there any pending litigation against the firm, involving the Government of India, State Governments or any Government agencies, on matters relating to financial impropriety, money laundering and/or tax evasion? If yes, please provide additional details.	Yes/No

The undersigned declares that all information, statements and description contained in this document is correct in all respects and complete to the best of my knowledge and belief.

Signature.....

Name of the signatory.....

Company Name.....

Note: - In case any figures or information given therein are found to be incorrect and/ or certificates/documents provided in support of the relevant information entered therein are found to be fabricated, the contract will not be considered for inclusion under the credit facility.

Applicant's JV Member's Information Form

S.No.	Details required
1.	Applicant Name:
2.	Applicant's JV Member's name:
3.	Applicants JV Member's country of registration:
4.	Applicants JV Member's date of constitution:
5.	Applicants JV Member's legal address registered in India:
6.	Applicants JV Member's authorized representative information- Name: Address: Telephone/Fax No: Email address:

Form D

(Exporter's Bank letter head)

----- (date)

(Importer's Bank and Address)

Dear Sir

Agreement on Receiving Payments in Indian Rupees (INR)

Name of Exporter and Address -

Performa Invoice No -

Date -

Value in USD -

I do hereby agree to receive the payment for the aforementioned consignment of goods supplied to (importers name and address), in Indian Rupee terms (INR) through the Indian Credit Facility for year 2022 agreed between the Government of India and the Government of Sri Lanka.

This letter is issued on the request of the Exporter

.....
(Signature of Authorized Officer
the Exporter's Bank and designation)

.....
(Date and Seal) of

Form E**AFFIDAVIT**

The undersigned declares that all information, statements and description contained in the Application is correct in all respects and complete to the best of our knowledge and belief.

We understand that in case any figures or information given therein are found to be incorrect and/ or certificates/documents provided in support of the relevant information entered therein are found to be fabricated, the contract will not be considered for inclusion under the credit facility

Name of firm/company:**Signature(s) of authorized representative(s) of the Applicant:****Name of signatory:****In the capacity of:****Address:****Date:**

GOODS DETAILS													BANK INFORMATION				
ADDRESS	DESCRIPTION OF GOODS EXPORTED	HSBILL NO/HS CODE	AMOUNT OF INVOICE	AMOUNT PAYABLE INCLUDING MISC. CHARGES	COUNTRY OF ORIGIN OF GOODS	SHIPMENT DATE	SHIPMENT FROM (country)	SHIPMENT FROM (PORT)	SHIPMENT TO (COUNTRY)	SHIPMENT TO (PORT)	COUNTRY OF ORIGIN (EXPORTER)	VESSEL NAME/IMO NO.	BANK NAME	BIC CODE	AD BANK DETAILS	ACCOUNT NUMBER	IEC CODE OF THE EXPORTER

EXPORT
ER
NAME

MSD Order List No :2022/SPC/X/C/P/00298

	SR	ITEM DESCRIPTION	QUANTITY		DELIVERY SCHEDULE
1	00303304	<p>Paracetamol Suppository 125mg</p> <p>Paracetamol suppositories BP 125mg. Each suppository to contain 125mg of Paracetamol BP in a suitable suppository basis.</p> <p>OR</p> <p>Acetaminophen suppositories USP 125mg. Each suppository to contain 125mg of Acetaminophen USP in a suitable suppository basis.</p> <p>Note:</p> <p>1.The product should be stable for 24 months when stored at controlled room temperature(15'C-25'C.)</p> <p>2.Each suppository should be labelled accordingly</p> <p>Pack Size – 10 Suppositories in a Box</p>	10,000	SUPP	<p>5,000 Supp – 30th April 2022</p> <p>5,000 Supp – 30th July 2022</p>
2	00405302	<p>Albumin solution (human) 5%, 250ml</p> <p>Albumin solution BP/Ph Eur(human), 5% in 250ml bottle Each 250ml bottle to contain 5% of Albumin solution BP and at least 95% of the Albumin Protein BP (Ph Eur) derived from human plasma serum.</p> <p>OR</p> <p>Albumin Human USP 5% in 250ml bottle Each 250ml bottle to contain 5% of Albumin Human USP 5% and at least 95% of the Albumin Protein USP derived from human plasma serum.</p> <p>Note:</p> <p>1.The product should ensure, at least two steps of virus inactivation as recommended by WHO.</p> <p>2.The product should be stable for minimum of 02 years when stored under 2'C - 8'C.</p> <p>3.Each bottle should be labeled accordingly</p> <p>Pack Size – 1 Bottle in a Box</p>	10,000	BOT	<p>5,000 Bottles – 01st April 2022</p> <p>5,000 Bottles – 30th July 2022</p>
3	00405801	<p>Eltrombopag Tablet 50mg</p> <p>Eltrombopag Tablet 50mg Each tablet to contain Eltrombopag olamine equivalent to 50 mg of Eltrombopag.</p> <p>Note:</p> <p>02.The shelf life of the product should be minimum of 24 months</p> <p>Pack Size – 10 Tablets in a Box</p>	25,000	TAB	<p>25,000 Tabs – 01st April 2022</p>

4	00601101	<p>Varicella vaccine 0.5ml Vial</p> <p>Varicella Vaccine Live BP single dose vials Each single dose vial of freeze - dried vaccine (live) to contain attenuated OKA strain of Varicella virus BP</p> <p>Packing: 0.5ml (single dose vial)</p> <p>Note:</p> <ul style="list-style-type: none"> i. Vaccines recommended for bulk purchase by the WHO for UN agencies will be considered as an added advantage (WHO pre-qualified). ii. The following documents should be submitted pre- shipment for each lot of vaccine despatched. (a). Invoice (b). Certificate of origin (c). Certificate of analysis. (d). Lot release certificate from National control Laboratory (NCL) from country of origin. (e). Summary lot protocols of production procedure & quality control testing. These documents should be submitted pre shipment to the National Control Laboratory for Vaccines (MRI) Sri Lanka. iii.Each consignment should have a minimum shelf life of 20 months at the time of despatch. iv.The vaccine should also comply with the general requirements for vaccine in the B.P. or U.S.P. v.The vaccine should meet the most recent requirements of W.H.O. when tested by the methods outlined by WHO. vi.Cold chain Monitors should be included in each pack and the Cold Chain should be maintained according to the manufacturer's instructions during storage, transport and delivery of vaccine. vii.The vaccine should be stored at temperature between +2'C and + 8'C. viii.Each vial should be provided with a suitable sterile diluent. ix.Each vial should be labeled accordingly indicating batch No., date of manufacture and expiry. x. Director/MSD should be informed two weeks prior to the arrival of vaccine. 	300	VIAL	300 vials – 30 th April 2022
		Pack Size – 1 vial in a Box			

5	00305302	<p>Botulinum Toxin 50IU vial</p> <p>Botulinum A Toxin Each vial to contain 50IU of Botulinum A toxin haemagglutinin complex as sterile powder for reconstitution.</p> <p>Note: 1. This injection should be stable for minimum of 24 months when stored at a temperature of 2'C-8'C 2.Each vial should be labelled accordingly.</p>	700	VIAL	<p>400 vials – 30th April 2022</p> <p>300 vials – 31st October 2022</p>
		Pack Size – 1 vial in a Box			
6	00802501	<p>Terlipressin acetate inj. 1mg vial</p> <p>Terlipressin acetate injection 1mg vial Each vial to contain 1mg of Terlipressin acetate as sterile, dry powder for reconstitution and solvent for solution for injection.</p> <p>Note: 1. This product should be stable for a minimum of 24 months when stored at a temperature below 25'C and protected from light. 2. Each vial should be labelled accordingly.</p> <p>OR</p> <p>Terlipressin Acetate Solution for Injection 1mg Ampoule Each ampoule to contain 1mg of Terlipressin BP as sterile and solution for Injection.</p> <p>Note: 01. This product should be stable for a minimum of 24 months when stored at a temperature of 2'C-8'C and protected from light. 02. Each ampoule should be labeled accordingly</p>	10,000	VIAL	<p>6,000 vials – 30th April 2022</p> <p>4,000 vials – 30th July 2022</p>
		Pack Size – 1 vial in a Box			
7	00400401	<p>Iron sucrose Inj. 100mg in 5ml</p> <p>Iron Sucrose solution for injection / Infusion Each 5ml ampoule to contain 20mg/ml of Iron as Iron Sucrose solution for intravenous injection or intravenous infusion.</p> <p>Note: 1. The product should be stable for a minimum of 24 months when stored at a temperature range of 28'C-32'C 2. Each ampoule should be labelled accordingly.</p>	60,000	AMP	<p>30,000 Amps – 01st May 2022</p> <p>30,000 Amps – 30th September 2022</p>
		Pack Size – 1 Ampoule in a Box			

8	00206302	<p>Prothrombin Complex Concentrate Injection 500IU</p> <p>Prothrombin Complex Concentrate Injection 500IU Vial</p> <p>[I. The active substance – Human Coagulation Factor II Human Coagulation factor VII – Quantity per ML reconstituted solution should be 10-25 iu/ml Human Coagulation factor IX – Quantity per 500 IU vial should be 500IU Huma Coagulation Factor X II. Further active ingredients – Protein C & protein S].</p> <p>Each vial to contain sterile mixture of lyophilized Human Prothrombin (Factors II) and Factors VII,IX,and X concentrates derived from human plasma, for intravenous injection.</p> <p>Note:</p> <ol style="list-style-type: none"> 1. The item should be stable at temperature 2'C - 8'C. 2. The product should have minimum 24 months shelf life at the time of delivery to MSD. 3. Tender should submit detail specifications of the product offered including a product leaflet. 4. The product should ensure, at least two steps on virus inactivation as recommended by WHO/US.FDA 5. The donor selection process should be specified by the manufacturer. 6. Each batch should be certified as free from HIV and hepatitis viruses. 7. Anti viral test methods used for screening for HIV and Hepatitis viruses should be declared by the manufacturer. This test methods used should be approved by WHO/US.FDA. 8. Each vial to be submitted with suitable diluent. 9. The product should be protected from light. 10. Product content should be printed in the label of the vial as well as in the box. 11. The product should have the CDDA registration. 	300	VIAL	300 vials – 31 st March 2022
		Pack Size – 1 vial in a Box			

MSD Order List No :2022/SPC/X/C/P/00331

9	01210201	Azacitidine Inj. 100mg vial Azacitidine Injection 100mg vial, Each vial to contain 100mg of Azacitidine for subcutaneous and intravenous use. Note: 1. The product should be stable for 24 months when stored at a temperature of 28'C-32'C. 2. Each vial should be labelled accordingly	2,000	VIAL	1,000 vials – 28 th April 2022
		Pack Size – 1 Vial			500 vials – 04 th September 2022 500 vials – 30 th November 2022
10	01202901	Bevacizumab inj. 100mg/4ml vial Bevacizumab Injection 100mg/4ml Each 4ml vial to contain 100mg of Bevacizumab for intravenous infusion. Note : 1.The product should be stable for a minimum of 24 months when stored within a temperature range of 2'C-8'C. 2.Each vial should be labelled accordingly.	10,000	VIAL	5,000 vials – 28 th April 2022
		Pack Size – 1 vial in a pack			2,500 vials – 01 st September 2022 2,500 vials – 30 th November 2022
11	01201102	Doxorubicin con. (Lipsoml) Inj. 20mg/10ml Concentrated (Liposomal) Doxorubicin hydrochloride for intravenous infusion 20mg in 10ml vial Each 10ml vial to contain sterile solution of 20mg Doxorubicin hydrochloride BP/USP encapsulated in liposomes suitable for intravenous infusion. Note: 1. The injection should be stable for a minimum of 24 months when stored within temperature range of 2'C - 8'C. 2. This injection should be protected from light. 3. Each vial should be labelled accordingly.	1,200	VIAL	600 vials – 28 th April 2022
		Pack Size – 1 vial in a pack			300 vials – 04 th September 2022 300 vials – 30 th November 2022
12	01204002	Dasatinib Tablet 50mg Dasatinib tablet 50mg Each tablet to contain 50 mg of Dasatinib (as monohydrate). Note: 01.The shelf life of the product should be minimum of 24 months	23,000	TAB	11,500 Tabs – 28 th April 2022
		Pack Size – 1 TAB			5,000 Tabs – 30 th September 2022 6,500 Tabs – 23 rd November 2022

13	01204003	Dasatinib tablet 20mg Dasatinib tablet 20mg Each tablet to contain 20 mg of Dasatinib (as monohydrate). Note: 01.The shelf life of the product should be minimum of 24 months	3,500	TAB	1,800 Tabs – 28 th April 2022 1,000 Tabs – 04 th September 2022 700 Tabs – 30 th November 2022
		Pack Size – 1 TAB			
14	01401802	Denosumab inj. 60mg in 1ml Denosumab injection 60mg in 1ml	500	PFSY	250 PF.Syr – 28 th April 2022 125 PF.Syr – 04 th September 2022 125 PF.Syr – 30 th November 2022
		Pack Size – 1 PFSY			
15	01204101	Erlotinib hydrochloride tablet 150mg Erlotinib Hydrochloride tablet 150mg Each tablet to contain 150mg of Erlotinib Hydrochloride. Note: 01.The shelf life of the product should be minimum of 24 months	10,000	TAB	5,000 Tabs – 28 th April 2022 2,500 Tabs – 04 th September 2022 2,500 Tabs – 30 th November 2022
		Pack Size – 1 TAB			
16	01204202	Everolimus tablet 10mg Everolimus Tablet 10mg Each tablet to contain 10 mg everolimus Note: 01.The shelf life of the product should be minimum of 24 months	6,000	TAB	3,000 Tabs – 28 th April 2022 1,500 Tabs – 04 th September 2022 1,500 Tabs – 30 th November 2022
		Pack Size – 1 TAB			
17	01211701	Enzalutamide Cap 40mg Enzalutamide capsule 40mg Each capsule to contain 40mg of Enzalutamide. Note: The shelf life of the product should be minimum of 24 months.	30,000	CAP	15,000 Caps – 28 th April 2022 7,500 Caps – 04 th September 2022 7,500 Caps – 30 th November 2022
		Pack Size – 1 CAP			

18	01211601	Eribulin Mesylate injection 1mg/2ml vial Eribulin Mesylate injection 1mg/2ml vial	150	VIAL	75 vials – 28 th April 2022 35 vials – 04 th September 2022 40 vials – 30 th November 2022
		Pack Size – 1 VIAL			
19	01201801	Fludarabine phosphate inj. 50mg vial Fludarabine Phosphate for injection USP, 50mg vial Each vial to contain Fludarabine Phosphate USP, powder for solution for intravenous use. Note: 1. This injection should be stable for a minimum of 24 months when stored at a temperature of below 30'C 2. Each vial should be labelled accordingly.	200	VIAL	100 vials – 28 th April 2022 50 vials – 04 th September 2022 50 vials – 30 th November 2022
		Pack Size – 1 VIAL			
20	01210501	Fulvestrant Inj. 250mg/5ml PFS Fulvestrant solution for injection 50mg/ml, 5ml pre- filled syringe Each pre-filled syringe to contain 250 mg of fulvestrant in 5 ml solution. Note: 1. This injection should be stable for a minimum of 24 months when stored within temperature range of 2'C - 8'C. 2.Each pre-filled syringe should be labelled accordingly.	3,000	PFSY	1,500 PF.Syr – 28 th April 2022 750 PF.Syr – 29 th September 2022 750 PF.Syr – 30 th November 2022
		Pack Size – 1 PFSY			
21	01204301	Gefitinib tablet 250mg Gefitinib tablet 250mg Each tablet to contain 250mg of Gefitinib Note: 01. The shelf life of the product should be minimum of 24 months	10,000	TAB	5,000 Tabs – 28 th April 2022 2,500 Tabs – 29 th September 2022 2,500 Tabs – 30 th November 2022
		Pack Size – 1 TAB			

22	01204501	Lapatinib Tablet 250mg Lapatinib tablet 250mg Each tablet to contain 250mg of Lapatinib. Note: 01.The shelf life of the product should be minimum of 24 months	83,000	TAB	43,000 Tabs – 29 th April 2022 20,000 Tabs – 29 th September 2022 20,000 Tabs – 30 th November 2022
		Pack Size – 1 TAB			
23	01212101	Lenvatinib capsule 10mg Lenvatinib Capsule 10 mg	7,000	CAP	3,500 Caps – 04 th April 2022 2,000 Caps – 29 th September 2022 1,500 Caps – 30 th November 2022
		Pack Size – 1 CAP			
24	01212102	Lenvatinib capsule 4mg Lenvatinib Capsule 04 mg	2,000	CAP	1,000 Caps – 03 rd April 2022 1,000 Caps – 04 th September 2022
		Pack Size – 1 CAP			
25	01209901	Osimertinib Tab 80 mg Osimertinib (as mesylate) film-coated tablet 80 mg Each tablet to contain 80 mg of osimertinib as mesylate. Note: 01.The shelf life of the product should be minimum of 24 months.	35,000	TAB	15,000 Tabs – 04 th April 2022 10,000 Tabs – 29 th September 2022 10,000 Tabs – 30 th November 2022
		Pack Size – 1 TAB			
26	01211501	Olaparib Cap 50mg Olaparib capsule 50mg Each capsule to contain 50mg of Olaparib. Note: The shelf life of the product should be minimum of 24 months	100,000	CAP	50,000 Caps – 27 th April 2022 25,000 Caps – 04 th September 2022 25,000 Caps – 30 th November 2022
		Pack Size – 1 CAP			

27	01208101	Pazopanib Tablet 200mg Pazopanib tablet 200mg Each tablet to contain 200 mg Pazopanib (as hydrochloride) Note: 01.The shelf life of the product should be minimum of 24 months	54,000	TAB	27,000 Tabs – 28 th April 2022 17,000 Tabs – 04 th September 2022 10,000 Tabs – 30 th November 2022
		Pack Size – 1 TAB			
28	01211301	Palbociclib Cap. 125mg Palbociclib Capsule 125mg	35,000	CAP	15,000 Caps – 28 th April 2022 10,000 Caps – 28 th September 2022 10,000 Caps – 30 th November 2022
		Pack Size – 21 Capsules in a pack			
29	01210901	Pertuzumab injection 420mg/14ml vial Pertuzumab injection 30mg/ml 14ml vial Each vial of concentrate to contain Pertuzumab at a concentration of 30 mg/ml 14mlvial Note: 1. This injection should be stable for a minimum of 24 months when stored within temperature of 2°C – 8°C. 2.Each vial should be labelled accordingly.	300	VIAL	150 vials – 28 th April 2022 75 vials – 04 th September 2022 75 vials – 24 th November 2022
		Pack Size – 1 VIAL			
30	01206201	Filgrastim (Pegylated) inj. 6mg in 0.6ml – 1ml vial/PFS Pegylated Filgrastim Injection 6mg/0.6ml-1ml Each vial/pre-filled syringe to contain 6 mg of pegylated filgrastim in 0.6 ml-1ml solution for injection. Note: 1. Shelf life of the product should be minimum of 24 months 2.Each vial/pre-filled syringe should be labelled accordingly.	1,200	VIAL	600 vials – 28 th April 2022 300 vials – 04 th September 2022 300 vials – 30 th November 2022
		Pack Size – 1 VIAL			

31	01203203	<p>Peg-asparaginase Inj 3,750IU</p> <p>Peg-asparaginase injection 3750 IU Each 5 ml vial to contain pegaspargase equivalent to 3750 I.U. for Solution for injection</p> <p>Note :</p> <ol style="list-style-type: none"> 1.This injection should be stable for a minimum of 24 months when stored at a temperature range of 2'C-8'C 2.Each vial should be labelled accordingly. 	270	VIAL	<p>135 vials – 28th April 2022</p> <p>85 vials – 04th September 2022</p> <p>50 vials – 30th November 2022</p>
		Pack Size – 1 VIAL			
32	01204903	<p>Paclitaxel(protein-bound) inj. 100mg vial</p> <p>Paclitaxel protein bound particles for injectable suspension 100mg vial Each 100mg vial to contain Paclitaxel protein bound (Albumin bound) particles for injectable suspension for intravenous use.</p> <p>Note:</p> <ol style="list-style-type: none"> 1.This injection should be stable for a minimum of 24 months when stored under manufacturer's conditions. 2.Each vial should be labeled accordingly 3.To be supplied with suitable diluents and administration device, compatible for Paclitaxel protein-bound (albumin bound) particles for injectable suspension. 	2,400	VIAL	<p>1,200 vials – 28th April 2022</p> <p>600 vials – 04th September 2022</p> <p>600 vials – 25th November 2022</p>
		Pack Size – 1 VIAL			
33	01204906	<p>Paclitaxel Nanoparticle Inj. 300mg</p> <p>Paclitaxel Nanoparticle Injection 300mg Each vial to contain 300 mg of Paclitaxel formulated as albumin bound nanoparticles.</p> <ol style="list-style-type: none"> 1.This product should be stable for a minimum of 24 months when stored at a temperature range of 28'C-32'C. 2.Each vial should be labelled accordingly. 3.One set of administration device and suitable diluent compatible with Paclitaxel Nanoparticle injection, to be supplied with each vial of Paclitaxel Nanoparticle injection. <p>Administration device sets should be</p> <ol style="list-style-type: none"> 3.1.Free from Polyvinyl Chloride (PVC) and di-(2-ethylhexyl) Phthalate (DEHP) 3.2.Contain needle, in line filter with a microspores membrane not greater than 0.22 micrometer and a poly ethylene- lined. 	1,700	VIAL	<p>800 vials – 28th April 2022</p> <p>450 vials – 04th September 2022</p> <p>450 vials – 30th November 2022</p>
		Pack Size – 1 VIAL			

34	01211001	<p>Regorafenib tablet 40mg</p> <p>Regorafenib tablet 40mg Each film-coated tablet to contain 40 mg of Regorafenib.</p> <p>Note: 01.The shelf life of the product should be minimum of 24 months.</p>	15,000	TAB	<p>7,500 Tabs – 28th April 2022</p> <p>4,500 Tabs – 04th September 2022</p> <p>3,000 Tabs – 30th November 2022</p>
		Pack Size – 1 TAB			
35	01204701	<p>Sunitinib Malate capsule 50mg</p> <p>Sunitinib Malate capsules 50mg Each capsule to contain 50mg of Sunitinib Malate.</p> <p>Note: 01.The shelf life of the product should be minimum of 24 months</p>	10,000	CAP	<p>5,000 Caps – 28th April 2022</p> <p>2,500 Caps – 04th September 2022</p> <p>2,500 Caps – 29th November 2022</p>
		Pack Size – 1 CAP			
36	01204702	<p>Sunitinib Malate capsule 12.5mg</p> <p>Sunitinib Malate capsules 12.5mg Each capsule to contain 12.5mg of Sunitinib Malate.</p> <p>Note: 01.The shelf life of the product should be minimum of 24 months</p>	1,500	CAP	<p>750 Caps – 28th April 2022</p> <p>400 Caps – 04th September 2022</p> <p>350 Caps – 30th November 2022</p>
		Pack Size – 1 CAP			
37	01210001	<p>Vandetanib tablet 100mg</p> <p>Vandetanib tablet 100mg Each film-coated tablet to contain 100mg of vandetanib.</p> <p>Note: 01. The shelf life of the product should be minimum of 24 months</p>	2,500	TAB	<p>1,250 Tabs – 28th April 2022</p> <p>750 Tabs – 04th September 2022</p> <p>500 Tabs – 30th November 2022</p>
		Pack Size – 1 TAB			

38	01205102	<p>Trastuzumab Injection 440mg</p> <p>Trastuzumab injection 440mg with solvent in 20ml vial Each 20ml vial to contain 440 mg of Trastuzumab with suitable solvent for intravenous use</p> <p>Note:</p> <ol style="list-style-type: none"> 1. The product should be stored at 2-8°C 2. Each vial should be labelled accordingly 3. The shelf life of the product should be minimum of 24 months 	4,000	VIAL	<p>2,000 vials – 27th April 2022</p> <p>1,000 vials – 11th September 2022</p> <p>1,000 vials – 29th November 2022</p>
		Pack Size – 1 VIAL			
39	01208001	<p>Topotecan hydrochloride inj. 2.5mg vial</p> <p>Topotecan Hydrochloride Injection 2.5mg Each 1 ml of concentrate for solution for infusion to contain 1 mg of topotecan (as hydrochloride).</p> <p>Note:</p> <ol style="list-style-type: none"> 1. This injection should be stable for a minimum 24 months when stored at a temperature range of 2°C - 8°C 2. Each vial should be labeled accordingly 	2,000	VIAL	<p>1,000 vials – 28th April 2022</p> <p>500 vials – 04th September 2022</p> <p>500 vials – 30th November 2022</p>
		Pack Size – 1 VIAL			
40	01210601	<p>Nivolumab Inj. 100mg/ 10ml vial</p> <p>Nivolumab injection 100mg/10ml vial Each mL of concentrate to contain 10 mg of Nivolumab</p> <p>Note:</p> <ol style="list-style-type: none"> 1. This injection should be stable for a minimum of 24 months when stored within temperature range of 2°C - 8°C. 2.Each vial should be labelled accordingly. 	600	VIAL	<p>250 vials – 28th April 2022</p> <p>250 vials – 04th September 2022</p> <p>100 vials – 30th November 2022</p>
		Pack Size – 1 VIAL			
41	01207302	<p>Goserelin Acetate Implant 10.8mg (in syringe applicator)</p> <p>Goserelin Acetate 10.8mg implant in syringe applicator. Each implant to contain Gosereline Acetate Ph Eur 10.8mg for subcutaneous use.</p> <p>Note;</p> <ol style="list-style-type: none"> 1. The product should be stable for a minimum of 02 years when stored below 25° C and Protected from light 2.Each implant should be labelled accordingly. 	500	PFSY	<p>250 PF.Syr – 28th April 2022</p> <p>150 PF.Syr – 05th September 2022</p> <p>100 PF.Syr – 23rd November 2022</p>
		Pack Size – 1 PFSY			

42	01209501	<p>Tretinoin Capsule 10mg</p> <p>Tretinoin Capsule 10mg Each capsule to contain 10 mg of tretinoin BP/USP Note: 01.The shelf life of the product should be minimum of 24 months.</p>	6,000	CAP	<p>3,000 Caps – 27th April 2022</p> <p>1,500 Caps – 05th September 2022</p> <p>1,500 Caps – 30th November 2022</p>
		Pack Size – 1 CAP			
43	01204905	<p>Paclitaxel Nanoparticle inj. 100mg vial</p> <p>Paclitaxel Nanoparticle Injection 100mg Each vial to contain 100 mg of Paclitaxel formulated as albumin bound nanoparticles. 1.This product should be stable for a minimum of 24 months when stored at a temperature range of 28'C-32'C. 2.Each vial should be labelled accordingly. 3.One set of administration device and suitable diluent compatible with Paclitaxel Nanoparticle injection,to be supplied with each vial of Paclitaxel Nanoparticle injection. Administration device sets should be 3.1.Free from Polyvinyl Chloride (PVC) and di-(2-ethylhexyl) Phthalate (DEHP) 3.2.Contain needle, in line filter with a microspores membrane not greater than 0.22 micrometer and a poly ethylene- lined.</p>	1,000	VIAL	<p>500 vials – 05th April 2022</p> <p>250 vials – 05th September 2022</p> <p>250 vials – 29th November 2022</p>
		Pack Size – 1 VIAL			